Immunotherapy in Gynecologic Cancers: A Focus on Checkpoint Inhibition
Immunotherapy is an emerging treatment option for gynecologic cancers.
Immunotherapy aims to eliminate cancer cells by (re)initiating the anticancer response of the patient’s own immune system. Checkpoint inhibitors, a type of immunotherapy, have been FDA-approved for the treatment of a variety of cancer types, including some gynecologic cancers. Numerous trials are underway to determine the clinical efficacy of checkpoint inhibitors alone or in combination with other therapies for the treatment of advanced/recurrent endometrial, cervical, and ovarian cancers. Although checkpoint inhibitors are associated with a well-characterized pattern of inflammatory side effects, management guidelines are available.
Explore the module further to learn more about immunotherapy in gynecologic cancers—or download the module for later review offline.
To review strategies for managing immune-related adverse events (irAEs) in patients treated with checkpoint inhibitors, see the Understanding and Managing Immune-Related Adverse Events Associated With Checkpoint Inhibition module.